

Table of Contents

1.	Overview of Cellular LanthaScreen® Technology	1
2.	Materials Supplied	2
3.	Materials Required, but Not Supplied	2
4.	Cell Culture Conditions	3
4.1	Media Required	3
4.2	Growth Conditions	3
5.	Assay Procedure	4
5.1	Quick Reference Guide	4
5.2	Detailed Assay Protocol	4
5.3	Detection	5
6.	Data Analysis	6
6.1	Background Subtraction (optional)	6
6.2	Representative Data	6
7.	Detailed Cell Handling Procedures	6
7.1	Thawing Method	6
7.2	Propagation Method	7
7.3	Freezing Method	7
8.	Purchaser notification	8

1. Overview of Cellular LanthaScreen® Technology

Time-resolved FRET (TR-FRET) has been recognized as a method to overcome interfering signals from compounds in high-throughput screening applications. Similar to standard FRET-based assays, TR-FRET relies on the proximity dependent energy transfer between an excited donor fluorophore and a suitable acceptor fluorophore, which can be detected by an increased emission from the acceptor molecule. Invitrogen's LanthaScreen® TR-FRET technology uses a long life time terbium chelate (Tb) as the donor species which is unique in its extended excited state lifetime. This time period is in the range of milliseconds as opposed to nanoseconds (1000-fold longer) for the majority of fluorophores. This unique feature allows the measurement of FRET between terbium and the acceptor molecule after a time delay, typically 50–100 microseconds after excitation by a flash lamp excitation source. This delay overcomes interference caused by such things as autofluorescent compounds and precipitate induced light scatter. A complete guide to commonly asked questions and answers regarding LanthaScreen® technology can be found at www.invitrogen.com/lanthascreen.

The LanthaScreen® GFP cellular assays represent a unique and sensitive way to utilize TR-FRET technology for the interrogation of specific molecular steps within endogenous signal transduction cascades. By expressing specific target proteins as fusions with green fluorescent protein (GFP, a suitable TR-FRET acceptor for the excited-state Tb fluorophore) in living cells, modification-specific antibodies labeled with Tb can be used to detect stimulus-induced post-translational modifications in a lysed-cell assay format.

The LanthaScreen® PRAS40 HEK293E cell line allows the accurate monitoring of the Akt-mediated phosphorylation of PRAS40 (at Thr-246) in response to insulin or insulin-like growth factor (IGF-1). Following activation of the Akt pathway, the change in phosphorylation state of the GFP-PRAS40 fusion proteins are detected in cell lysates using LanthaScreen® Tb-anti-pPRAS40 [pThr246] antibody. This assay has been designed in an "addition only" or "mix and read" format and is compatible for use in high-throughput screening applications.

2. Materials Supplied

Cell Line Name:	LanthaScreen® PRAS40 HEK293E
Description:	LanthaScreen® PRAS40 HEK293E cells contain a stably integrated expression vector encoding a GFP-PRAS40 fusion under control of a CMV promoter. The GFP-PRAS40 DNA expression construct was introduced into HEK293E cells using lentiviral transduction, followed by selection with Blasticidin. This cell line is a clonal population isolated by flow cytometry using GFP fluorescence as sorting marker.
Product Number:	K1528
Shipping Condition:	Dry Ice
Storage Condition:	Liquid nitrogen. Immediately upon receipt, cells must be stored in liquid nitrogen or thawed for immediate use. Cells stored at -80°C can quickly lose viability.
Quantity:	~16,000,000 (1.6 × 10 ⁷) cells/mL
Application:	Detection of phosphorylation of GFP-PRAS40; read-out of Akt signaling
Growth Properties:	Adherent
Cell Phenotype:	Epithelial
Selection Marker:	Blasticidin (5 µg/mL)
Vector Used:	—
Mycoplasma Testing:	yes
BioSafety Level:	2

3. Materials Required, but Not Supplied

Media/Reagents	Recommended Source	Part #
Recovery™ Cell Culture Freezing Medium	Invitrogen	12648-010
Dulbecco's Modified Eagle Medium (D-MEM) with GlutaMAX™-1 and sodium pyruvate	Invitrogen	10569-010
DMSO	Fluka	41647
Fetal bovine serum (FBS), dialyzed, tissue-culture grade (DO NOT SUBSTITUTE!)	Invitrogen	26400-044
D-MEM, low glucose, w/o L-glutamine or phenol red	Invitrogen	11054-020
Bovine Serum Albumin (BSA), 10% Ultrapure	Invitrogen	P2046
Non-Essential Amino Acids (NEAA)	Invitrogen	11140-050
Penicillin/Streptomycin (antibiotic)	Invitrogen	15140-122
HEPES (pH = 7.3)	Invitrogen	15630-080
Phosphate-buffered saline without calcium and magnesium [PBS(-)]	Invitrogen	14190-136
Trypsin/EDTA	Invitrogen	25300-062
Blasticidin (antibiotic)	Invitrogen	R210-01
LanthaScreen® Cellular Assay Lysis Buffer	Invitrogen	PV5598
LanthaScreen® Tb-anti-pPRAS40 [pThr246] Antibody	Invitrogen	PV5102
Lysis buffer	(see Section 5.2.6)	
Protease Inhibitor cocktail	Sigma Aldrich	P8340
Phosphatase Inhibitor cocktail	Sigma Aldrich	P2850
Trypan blue	Invitrogen	15250-061

Consumables	Recommended Source	Part #
White tissue culture treated, 384-well assay plates	Corning Life Sciences	3570

Equipment	Recommended Source
Fluorescence plate reader with top-read and TR-FRET capability	Various
Filters, if required for plate reader (see Section 5.3)	Various
Optional: Microplate centrifuge	Various

For Technical Support for this or other Drug Discovery Products, dial 760 603 7200, option 3, extension 40266

4. Cell Culture Conditions

4.1 Media Required

Component	Growth Medium	Assay Medium	Freezing Medium
Dulbecco's Modified Eagle Medium (D-MEM) with GlutaMAX™-1 and sodium pyruvate	90%	—	—
D-MEM, low glucose, w/o L-glutamine or phenol red	—	99.9%	—
Dialyzed FBS	10%	—	—
Bovine Serum Albumin (BSA)	—	0.1%	—
NEAA	0.1 mM	—	—
Penicillin (antibiotic)	100 U/mL	—	—
Streptomycin (antibiotic)	100 µg/mL	—	—
Sodium Pyruvate	1 mM	—	—
Blasticidin (antibiotic)	5 µg/mL	—	—
Recovery™ Cell Culture Freezing Medium	—	—	100%

Note: Unless otherwise stated, all media and solutions should be at room temperature or slightly higher (we recommend 37°C for optimal performance) before adding them to the cells.

4.2 Growth Conditions

For detailed cell growth and maintenance directions, see **Section 7**.

Note: We recommend passing cells for three passages after thawing before using them in this assay.

1. Thaw cells in Growth Medium without Blasticidin and culture them in Growth Medium with Blasticidin. Pass or feed cells at least twice a week and maintain them in a 37°C/5% CO₂ incubator. Maintain cells between 20% and 90% confluency. Do not allow cells to become over-confluent.
2. Freeze cells in Freezing Medium.

5. Assay Procedure

The following instructions outline the recommended procedure for monitoring the insulin-induced phosphorylation of GFP-PRAS40 using LanthaScreen® Tb-anti-pPRAS40 [pThr246] antibody.

5.1 Quick Reference Guide

For more detailed protocol information, see **Section 5.2**.

Plate layouts and experimental outlines will vary; in screening mode, we recommend using at least three wells for each condition: unstimulated, stimulated, and cell-free.

Note: Some solvents may affect assay performance. Assess the effect of a test compound solvent before screening

	Unstimulated Wells	Stimulated Wells	Cell-free wells
Step 1: Plate cells	32 μ L cells suspended in Assay Medium (20,000 cells/well)	32 μ L cells suspended in Assay Medium (20,000 cells/well)	32 μ L Assay Medium (no cells)
Step 2: Incubate cells	Incubate at 37°C/5% CO ₂ for 16–20 hours		
Step 3: Add DMSO	4 μ L per well of 1% DMSO in Assay Medium		
Step 4: Stimulate cells	4 μ L Assay Medium	4 μ L 10x insulin in Assay Medium (30 minutes)	4 μ L Assay Medium
Step 5: add Lysis Buffer (incl. Tb-Ab)	30 μ L per well		
Step 6: Cell Lysis/Assay Equilibration	60 minutes at room temperature (protect plate from light)		
Step 7: Read Plate/ Analyze data	See Section 6		

5.2 Detailed Assay Protocol

Plate layouts and experimental outlines will vary; in screening mode, we recommend using at least three wells for each control: unstimulated control, stimulated control, and cell-free control.

Note: Some solvents may affect assay performance. Assess the effects of solvent before screening.

5.2.1 Precautions

- Work on a dust-free, clean surface.
- If pipetting manually, you may need to centrifuge the plate briefly at room temperature (30 seconds at 14 \times g) after additions to ensure all assay components are on the bottom of the wells.
- Cells should be grown to reach 80–95% confluency before performing the assay.

5.2.2 Plate Cells

1. Harvest cells from culture in Growth Medium and resuspend in Assay Medium at a density of 6.25×10^5 cells/mL.
2. Plate the cells into a white tissue-culture treated 384-well plate. Add 32 μ L of Assay Medium to each cell-free control well. Add 32 μ L of cell suspension to each unstimulated and stimulated well.
3. After plating, centrifuge the plate briefly at room temperature (30 seconds at 14 \times g).
4. Incubate the plate in a 37°C/5% CO₂ incubator for 16–20 hours.

5.2.4 Stimulate Cells

1. Prepare 10X insulin at EC₈₀ in Assay Medium. We recommend preparing a dose response curve for insulin to determine the EC₈₀ for your Stimulation Solution.
2. Add 4 µL of Assay Medium to each unstimulated, stimulated, and cell-free well.
3. Add 4 µL of 10X insulin in Assay Medium to each stimulated well and 4 µL of Assay Medium to each unstimulated and cell-free well.
4. Incubate the assay plate in a humidified 37°C/5% CO₂ incubator for 60 minutes.

5.2.5 Lysis Buffer Preparation and Cell Lysis

1. LanthaScreen® Cellular Assay Lysis Buffer can be purchased from Invitrogen (Catalog number PV5598) or can be prepared as follows: 20 mM Tris-HCl, pH 7.4, 5 mM EDTA, 5 mM NaF, 150 mM NaCl, 1% NP-40 (or equivalent). This incomplete lysis buffer can be prepared in large batches and stored at -20°C. The complete lysis buffer (consisting of phosphatase and protease inhibitor cocktails as well as the LanthaScreen® Tb-anti-pPRAS40 [Thr246] antibody) should be prepared on the day of the experiment.
2. Determine the volume of complete lysis buffer needed for the assay (assuming 30 µL/well). Add 1/100 volume of each protease inhibitor and phosphatase inhibitor cocktail to the incomplete lysis buffer. Mix well by inversion several times. **Note:** Commonly used phosphatase inhibitors such as sodium orthovanadate (NaVO₄) and sodium pyrophosphate can interfere with the integrity of Tb chelate and should be avoided.
3. Add LanthaScreen® Tb-anti-pPRAS40 [pThr246] antibody to the lysis buffer to a final concentration of 5 nM. Mix gently by inversion several times.
4. Remove assay plate from the humidified 37°C/5% CO₂ incubator.
5. Add 30 µL of complete lysis buffer to each well of cells in media, and cover the plate to protect from light and evaporation.
6. Incubate the covered plate at room temperature for 60 minutes.

5.3 Detection

All TR-FRET measurements are to be made at room temperature from the top of the wells, preferably in 384-well, low-volume white assay plates with low fluorescence background.

5.3.1 Instrumentation, Filters, and Plates

The data presented in this document were generated using a BMG PHERAstar plate reader using the LanthaScreen® filter block available from BMG. The assay can be performed on a variety of plate readers, including those from Tecan. We do not recommend the use of monochromator-based instruments for LanthaScreen® GFP Cellular Assays, as the sensitivity of these instruments is not sufficient to adequately detect the endogenously expressed GFP fusion proteins. Visit www.invitrogen.com/lanthascreen or contact Invitrogen Discovery Sciences technical support at 800-955-6288 (select option 3 and enter 40266), or email tech_support@invitrogen.com for more information on performing LanthaScreen® assays on your particular instrument.

Recommended filters for the fluorescence plate reader:

Excitation filter:	337 nm
Donor Emission filter:	490 nm
Acceptor Emission filter:	520 nm
Integration start	100 µsec
Integration time	200 µsec

5.3.2 Reading an Assay Plate

1. Set the fluorescence plate reader to top/time-resolved read mode.
2. Allow the lamp in the fluorescence plate reader to warm up for at least 10 minutes before making measurements.
3. Use the following filter selections:

	Scan 1	Scan 2
Purpose:	Measure Donor (Terbium) Signal	Measure Acceptor (TR-FRET to GFP) Signal
Excitation filter:	337 nm	337 nm
Emission filter:	490 nm	520 nm

4. Calculate the acceptor/donor Emission Ratio (TR-FRET Ratio) for each well, by dividing the acceptor emission values by the donor emission values.

6. Data Analysis

6.1 Background Subtraction (optional)

1. Use the assay plate layout to identify the location of the cell-free wells. These control wells are used for background subtraction.
2. Determine the average 520/490 nm emission ratio from the cell-free wells (average antibody background).
3. Subtract the average antibody background (520/490 nm ratio) from all of the emission ratio data.

6.2 Representative Data




Figure 1. Insulin dose-response curve. LanthaScreen® PRAS40 HEKHEK293E cells (20,000 cells/well in 32 μ L of assay medium, 384-well format) were plated the day prior to the assay. On the day of the assay, cells were pretreated with 4 μ L of 1% DMSO before treatment with the indicated concentration of insulin (4 μ L addition) for 30 minutes. Cells were lysed by addition of 30 μ L lysis buffer (to 70 μ L total volume), which included both 5 nM of LanthaScreen® Tb-anti-pPRAS40 [pThr246] antibody and protease/phosphatase inhibitors. The plate was incubated for 60 minutes at room temperature. Fluorescence emission values at 520 nm and 490 nm were obtained using a BMG PHERAstar plate reader set to TR-FRET mode. The 520/490 nm emission ratios are plotted for each experiment, with 8 replicates at each data point.

7. Detailed Cell Handling Procedures

7.1 Thawing Method

1. Place 29 mL of Growth Medium without Blasticidin into a T225 flask.
2. Place the flask in a humidified 37°C/5% CO₂ incubator for 15 minutes to allow medium to equilibrate to the proper pH and temperature.
3. Remove the vial of cells to be thawed from liquid nitrogen and thaw rapidly by placing at 37°C in a water bath with gentle agitation for 1–2 minutes. Do not submerge vial in water.
4. Decontaminate the vial by wiping with 70% ethanol before opening in a Class II biological safety cabinet.
5. Transfer the vial contents drop-wise into 10 mL of Growth Medium without Blasticidin in a sterile 15-mL conical tube.
6. Centrifuge cells at 400 \times g for 5 minutes.
7. Aspirate supernatant and resuspend the cell pellet in 1 mL of fresh Growth Medium without Blasticidin.
8. Transfer contents to the T225 tissue culture flask containing pre-equilibrated Growth Medium without Blasticidin and place flask in a humidified 37°C/5% CO₂ incubator.
9. At first passage, switch to Growth Medium with Blasticidin.

7.2 Propagation Method

1. Cells should be passaged or fed at least twice a week. Cells should be maintained between 20% and 90% confluence. Do not allow cells to become over-confluent.
2. To passage cells, aspirate medium, rinse once in PBS, add Trypsin/EDTA (3 mL for a T75 flask and 5 mL for a T175 flask and 8 mL for T225 flask) and swirl to coat the cells evenly. Cells usually detach after 2–5 minutes upon exposure to Trypsin/EDTA. Add an equal volume of Growth Medium to inactivate Trypsin.
3. Verify under a microscope that cells have detached and clumps have completely dispersed.
4. Spin down cells at $400 \times g$ and resuspend in Growth Medium.

7.3 Freezing Method

1. Harvest the cells as described in **Section 7.2**. After detachment, count the cells, then spin cells down at $400 \times g$ and resuspend at the desired cell density in cold (4°C) Recovery™ Cell Culture Freezing Medium.
2. Dispense 1-mL aliquots into cryogenic vials.
3. Place in an insulated container for slow cooling and store overnight at -80°C .
4. Transfer to liquid nitrogen the next day for storage.

8. Purchaser notification

Limited Use Label License No. 5: Life Technologies Technology

The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. For products that are subject to multiple limited use label licenses, the terms of the most restrictive limited use label license shall control. Life Technologies Corporation will not assert a claim against the buyer of infringement of patents owned or controlled by Life Technologies Corporation which cover this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Life Technologies is willing to accept return of the product with a full refund. For information about purchasing a license to use this product or the technology embedded in it for any use other than for research use please contact Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008; Phone (760) 603-7200 or e-mail: outlicensing@lifetech.com.

Limited Use Label License No. 51: Blastidicin and the Blastidicin Selection Marker

Blasticidin and the blasticidin resistance gene (*bsd*) are the subject of U.S. Patent No. 5,527,701 sold under patent license for research purposes only. For information on purchasing a license to this product for purposes other than research, contact Licensing Department, Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.

Limited Use Label License No: 108 Lentiviral Technology

The Lentiviral Technology (based upon the *lentikat*TM system) is licensed from Cell Genesys, Inc., under U.S. Patent Nos. 5,834,256; 5,858,740; 5,994,136; 6,013,516; 6,051,427; 6,165,782 and 6,218,187 and corresponding patents and applications in other countries for internal research purposes only. Use of this technology for gene therapy applications or bioprocessing other than for non-human research use requires a license from Cell Genesys (Cell Genesys, Inc. 342 Lakeside Drive, Foster City, California 94404). The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity), including non-gene therapy research and target validation applications in laboratory animals.

Limited Use Label License No: 127 GFP with Heterologous Promoter

This product and its use is the subject of one or more of U.S. Patent Nos. 5,491,084 and 6,146,826, and foreign equivalents. This product is sold under license from Columbia University. Rights to use this product are limited to research use only, and expressly exclude the right to manufacture, use, sell or lease this product for use for measuring the level of toxicity for chemical agents and environmental samples in cells and transgenic animals. No other rights are conveyed. Not for human use or use in diagnostic or therapeutic procedures. Inquiry into the availability of a license to broader rights or the use of this product for commercial purposes should be directed to Columbia Innovation Enterprise, Columbia University, Engineering Terrace-Suite 363, New York, New York 10027.

Limited Use Label License No. 168: Lanthanide Chelates

This product is the subject of U.S. Patent No. 5,622,821, 5,639,615 and 5,656,433 and foreign equivalents licensed exclusively to Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) to not transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Life Technologies Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use, or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Life Technologies is willing to accept return of the product with a full refund. For information on purchasing a license to this product for purposes other than research, contact Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500. E-mail: outlicensing@lifetech.com.

Limited Use Label License No: 198 Fluorescent proteins and stable cell lines expressing such proteins (but not for vectors that contain the genes for such fluorescent proteins)

This product and its use is the subject of one or more of U.S. Patent Nos. 5,777,079, 6,066,476, and 6,319,669 and foreign equivalents. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for profit entity). No rights are conveyed to modify or clone the gene encoding GFP contained in this product. The buyer cannot sell or otherwise transfer (a) this product, (b) its components, or (c) materials made by the employment of this product or its components to a third party or otherwise use this product or its components or materials made by the employment of this product or its components for Commercial Purposes. The buyer may transfer information or materials made through the employment of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research. Life Technologies Corporation will not assert a claim against the buyer of infringement of the above patents based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer in which this product or its components was employed, provided that none of this product, or any of its components was used in the manufacture of such product. If the purchaser is not willing to accept the limitations of this limited use statement, Life Technologies Corporation is willing to accept return of the product with a full refund. For information on purchasing a license to use this product for purposes other than those permitted above, contact Licensing Department, Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, California 92008. Phone (760) 603-7200 or outlicensing@lifetech.com.

Limited Use Label License No: 267 Mutant GFP Products

This product and its use is the subject of one or more of U.S. Patent Nos. 6,090,919, 5,804,387, 5,994,077, and foreign equivalents.

Limited Use Label License No: 317 LentiVector® Technology

This product is licensed under U.S. Pat. Nos. 5,817,491; 5,591,624; 5,716,832; 6,312,682; 6,669,936; 6,235,522; 6,924,123 and foreign equivalents from Oxford BioMedica (UK) Ltd., Oxford, UK, and is provided for use in academic and commercial in vitro and in vivo research for elucidating gene function, and for validating potential gene products and pathways for drug discovery and development, but excludes any use of LentiVector® technology for: creating transgenic birds for the purpose of producing useful or valuable proteins in the eggs of such transgenic birds, the delivery of gene therapies, and for commercial production of therapeutic, diagnostic or other commercial products not intended for research use where such products do not consist of or incorporate a lentiviral vector. Information about licenses for commercial uses excluded under this license is available from Oxford BioMedica (UK), Ltd., Medawar Centre, Oxford Science Park, Oxford OX4 4GA UK enquiries@oxfordbiomedica.co.uk or BioMedica Inc 11622 El Camino Real #100, San Diego CA 92130-2049 USA. LentiVector is a registered US and European Community trade mark of Oxford BioMedica plc.

Use of Genetically Modified Organisms (GMO)

Information for European Customers: The LanthaScreen® GFP PRAS40 293E cell line is genetically modified with the plasmids pLenti6M3 pLenti-bsd/GFP PRAS40. As a condition of sale, use of this product must be in accordance with all applicable local legislation and guidelines including EC Directive 90/219/EEC on the contained use of genetically modified organisms.

© 2009, 2010 Life Technologies. All rights reserved. Reproduction forbidden without permission.